Brazil is a low-and-middle income country (LMIC) that, despite having a large population
and continental dimensions, has been able to successfully fight HIV/AIDS through a number …

The picture of HIV-1 genetic diversity in the global pandemic continues to evolve.
Identification of new variants, including circulating and unique recombinant forms …

Abstract Background Since January 2017, the recommended first-line antiretroviral regimen
in Brazil is the fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL+ D) …

Background. The prevalence of drug resistance among persons with newly acquired human
immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what …

The US Government has pledged to spend $15 billion in Africa and the Caribbean on AIDS.
A central focus of this plan is to provide antiretroviral treatment (ART) to millions. Here, we …

Objectives: To describe the molecular and epidemiological profile of HIV-1 in patients
followed at the University Hospital of Rio Grande, Brazil. Design and methods: A cross …

Use of antiretrovirals is widespread in Brazil, where more than 200,000 individuals are
under treatment. Although general prevalence of primary antiretroviral resistance in Brazil is …

Background HIV transmitted drug resistance (TDR) remains at moderate level in Latin
America and the Caribbean (LAC). However, different epidemiologic scenarios could …

Recombination is an important way to generate genetic diversity. Accumulation of HIV-1 full-
length genomes in databases demonstrated that recombination is pervasive in viral strains …

Objective: To investigate the origin and to reconstruct the onset date of the HIV-1 subtype C
epidemic in Brazil. Design: Three independent datasets of subtype C sequences isolated …